Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08NJE
|
||||
| Former ID |
DIB011286
|
||||
| Drug Name |
CR-845 iv infusion
|
||||
| Synonyms |
CR-845; Kappa opioid agonist (intravenous, pain), Cara/Ferring; Kappa opioid agonist (oral, pain), Cara/Ferring; Kappa opioid agonist (subcutaneous, pain), Cara/Ferring; CR-845 (iv infusion, pain), Cara/Ferring; CR-845 (oral capsule, pain), Cara/Ferring; CR-845 (subcutaneous, pain), Cara/Ferring; FE-202845 (iv, pain), Cara/Ferring; FE-202845 (oral, pain), Cara/Ferring; FE-202845 (sc, pain), Cara/Ferring
|
||||
| Indication | Pain [ICD9: 338, 356.0, 356.8,780; ICD10:G64, G90.0, R52, G89] | Phase 2/3 | [1] | ||
| Company |
Cara Therapeutics Inc; cara therapeutics
|
||||
| Target and Pathway | |||||
| Target(s) | Kappa-type opioid receptor | Target Info | Agonist | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Opioid prodynorphin pathway | |||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02542384) A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery. | ||||
| REF 2 | Peptide Kappa Opioid Receptor Ligands: Potential for Drug Development. AAPS J. 2009 June; 11(2): 312-322. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.